FDA Peptide Review
Publication Date: 4/14/2026 The Food and Drug Administration (FDA) is formally reviewing and weighing the option to potentially reclassify up to 14 peptides that were restricted under Category 2 in late 2023. This review process involves a series of public meetings by the Pharmacy Compounding Advisory Committee (PCAC) scheduled for later this year, and […]